The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index; none of the 21 sources its claims cite is checked for support yet.
Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease
Open accessAbstract
Nonalcoholic fatty liver disease is strongly associated with hepatic insulin resistance and type 2 diabetes mellitus, but the molecular signals linking hepatic fat accumulation to hepatic insulin resistance are unknown. Three days of high-fat feeding in rats results specifically in hepatic steatosis and hepatic insulin resistance. In this setting, PKCepsilon, but not other isoforms of PKC, is activated. To determine whether PKCepsilon plays a causal role in the pathogenesis of hepatic insulin resistance, we treated rats with an antisense oligonucleotide against PKCepsilon and subjected them to 3 days of high-fat feeding. Knocking down PKCepsilon expression protects rats from fat-induced hepatic insulin resistance and reverses fat-induced defects in hepatic insulin signaling. Furthermore, we show that PKCepsilon associates with the insulin receptor in vivo and impairs insulin receptor kinase activity both in vivo and in vitro. These data support the hypothesis that PKCepsilon plays a critical role in mediating fat-induced hepatic insulin resistance and represents a novel therapeutic target for type 2 diabetes.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In rats, 3 days of high-fat feeding causes hepatic steatosis and hepatic insulin resistance with specific activation of PKCε. Knocking down PKCε with an antisense oligonucleotide prevents fat-induced hepatic insulin resistance and improves hepatic insulin signaling, apparently by preventing PKCε from directly inhibiting insulin receptor kinase activity.
Key findings
- PKCε ASO specifically reduced PKCε expression in liver and white adipose tissue, but not muscle, without changing PKCδ; it caused no hepatotoxicity (AST: saline 57 ± 0.3 vs. PKCε 68 ± 3; ALT: saline 76 ± 3 vs. PKCε 87 ± 5), similar weight gain, and no differences in IL-6, leptin, adiponectin, or resistin.
- Despite unchanged liver triglyceride and DAG content and identical fasting plasma glucose, PKCε ASO lowered fasting plasma insulin by approximately 50% versus saline- and control ASO-treated rats, and improved hepatic insulin action: greater suppression of hepatic glucose production during hyperinsulinemic-euglycemic clamping, modestly increased whole-body glucose disposal, nearly 2-fold higher epididymal white adipose tissue glucose uptake, and greater suppression of plasma fatty acids.
- In PKCε ASO-treated rats, insulin increased IRS2 tyrosine phosphorylation approximately 300% above basal, whereas saline and control ASO rats failed to increase IRS2 phosphorylation; insulin-stimulated AKT2 activity increased approximately 400% versus approximately 50% in controls. Adipose insulin-stimulated AKT2 activity was 221% ± 16% in PKCε ASO rats versus 32% ± 11% and 23% ± 20% in saline- and control ASO-treated rats.
- PKCε coimmunoprecipitated with the insulin receptor in vivo, and increasing molar ratios of PKCε to insulin receptor-β dose-dependently decreased insulin receptor-β tyrosine kinase activity in vitro. Liver insulin receptor kinase activation by insulin was diminished in saline- and control ASO-treated high-fat-fed rats but preserved in PKCε ASO-treated rats.
Methods
- Male Sprague-Dawley rats weighing approximately 250 g were treated for 4 weeks with saline, control ASO, or PKCε ASO at 75 mg/kg per week by intraperitoneal injection, then fed a high-fat diet (26% carbohydrate, 59% fat, 15% protein calories; safflower oil major constituent) for 3 days.
- Hyperinsulinemic-euglycemic clamp studies used [6,6-2H]glucose and 2-deoxy-d-[1-14C]glucose to assess basal and insulin-stimulated glucose turnover and tissue glucose uptake; liver triglyceride and DAG, plasma hormones and fatty acids, insulin signaling, PKC expression, and insulin receptor kinase activity were measured.
- PKCε ASO was ISIS-232697; control ASO was ISIS-141923. A separate group of similarly treated rats underwent 20 minutes of hyperinsulinemic-euglycemic clamping for insulin signaling assays. Statistics used 1-way ANOVA followed by Tukey’s HSD test, with P < 0.05 considered significant.
Limitations
- The paper does not include a dedicated limitations section. It states that the role of PKCε in the adipocyte is uncertain and that a similar mechanism in patients with diabetes is hypothesized based on prior human data, not directly tested here.
- Evident from the text: the findings are in male Sprague-Dawley rats after only 3 days of high-fat feeding and 4 weeks of ASO treatment, so they cannot establish long-term causality, safety, or efficacy in human NAFLD or type 2 diabetes.
- Evident from the text: PKCε ASO reduced PKCε in liver and white adipose tissue but not muscle, and muscle glucose uptake was unchanged, limiting conclusions about skeletal muscle insulin action.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 21 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we show that PKCε associates with the insulin receptor in vivo and impairs insulin receptor kinase activity both in vivo and in vitro.”
- Also stated in: § PKCε interferes with insulin receptor activation. · plain
“Immunoprecipitation of insulin receptor from liver protein extracts pulled down PKCε, and immunoprecipitation of PKCε also pulled down insulin receptor (Figure 4D).”
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · boosted
“First, we show here that PKCε and insulin receptor directly associate in vivo, as they each coimmunoprecipitate the other.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § PKCε interferes with insulin receptor activation. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The reduction in mRNA translated into a similar reduction in PKCε protein content relative to that in saline-treated animals (Figure 1B).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Knocking down PKCε expression protects rats from fat-induced hepatic insulin resistance and reverses fat-induced defects in hepatic insulin signaling.”
- Also stated in: § PKCε ASO treatment does not alter liver lipids but lowers plasma insulin. · plain
“Under hyperinsulinemic conditions, suppression of hepatic glucose production was markedly greater in the PKCε group compared with the saline and control ASO groups (Figure 3B).”
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · boosted
“Here we establish that decreasing PKCε expression protects against the development of hepatic insulin resistance and improves adipose insulin action by augmenting the activity of the insulin signaling pathway.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § PKCε ASO treatment does not alter liver lipids but lowers plasma insulin. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, PKCε ASO treatment did not alter muscle PKCε expression.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Knocking down PKCε expression protects rats from fat-induced hepatic insulin resistance and reverses fat-induced defects in hepatic insulin signaling.”
- Also stated in: § PKCε ASO treatment improves insulin signaling. · plain
“In contrast, in rats treated with PKCε ASO, insulin increased IRS2 tyrosine phosphorylation approximately 300% above basal (Figure 4B).”
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · plain
“Thus, PKCε ASO treatment prevents the defects in insulin signaling that lead to the development of hepatic insulin resistance.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § PKCε ASO treatment improves insulin signaling. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The amount of PKCδ was unchanged by PKCε ASO treatment.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin receptor tyrosine phosphorylation was similarly increased above basal by approximately 50% in all 3 groups.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO treatment improves insulin signaling.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition to the changes in hepatic insulin action, there was a modest but significant increase in insulin-stimulated whole-body glucose disposal in the PKCε ASO-treated animals (Figure 3C).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO treatment does not alter liver lipids but lowers plasma insulin.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, analysis of the insulin signaling pathway demonstrated that insulin signaling was improved in PKCε-treated rats.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The lower insulin concentration approaches values seen in rats on regular (low-fat) chow and suggests improved hepatic insulin sensitivity.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO treatment does not alter liver lipids but lowers plasma insulin.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 10
- Probably not a substantial claim. 4
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“PKCε ASO treatment specifically reduced PKCε expression in liver and white adipose tissue after 4 weeks of treatment at 75 mg/kg per week (Figure 1A).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we show that PKCε associates with the insulin receptor in vivo and impairs insulin receptor kinase activity both in vivo and in vitro.”
- Also stated in: § PKCε interferes with insulin receptor activation. · hedged
“Increasing molar ratios of PKCε to insulin receptor-β resulted in a dose-dependent decrease in insulin receptor-β tyrosine kinase activity, suggesting that PKCε could directly inhibit insulin receptor kinase activity (Figure 4E).”
- Also stated in: § PKCε interferes with insulin receptor activation. · plain
“In contrast, insulin receptor obtained from PKCε ASO-treated rats had preserved activation of the insulin receptor kinase.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § PKCε interferes with insulin receptor activation. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neither fasting plasma glucose concentrations nor basal hepatic glucose production rates were affected by PKCε ASO therapy.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunoprecipitation of insulin receptor from liver protein extracts pulled down PKCε, and immunoprecipitation of PKCε also pulled down insulin receptor (Figure 4D).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε interferes with insulin receptor activation.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“PKCε ASO specifically inhibits PKCε, without altering the levels of other PKC isoforms.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specifically, rats remained free of hepatotoxicity, as reflected by the absence of transaminase elevation (aspartate aminotransferase [AST]: saline, 57 ± 0.3; PKCε, 68 ± 3; alanine aminotransferase [ALT]: saline, 76 ± 3; PKCε, 87 ± 5), and exhibited similar weight gain (Figure 1C) across all 3 groups.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Amelioration of nonalcoholic fatty liver disease (NAFLD) in patients with T2DM by weight reduction is associated with reversal of hepatic insulin resistance and a return to normoglycemia (9).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Introduction
What the sources say
- Not checked yetcites [9] Petersen, 2005, Diabetes. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“An alternate hypothesis is that the development of hepatic steatosis per se causes hepatic insulin resistance.”
- Also stated in: § Introduction · boosted
“multiple lines of evidence support the role of intrahepatic fat in causing hepatic insulin resistance (7)(8)(9)(10)(11)(12).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Introduction
What the sources say
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true.
- Also stated in: § Introduction · boosted
None of the sources cited for this claim have been checked yet.
In the paper
“Preventing fat accumulation by inhibiting lipid synthesis via disruption of the mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase (7) or promoting fat oxidation using either the mitochondrial uncoupler 2,4-dinitrophenol (10) or inhibition of acetyl-CoA carboxylase-1 and -2 (12) prevents PKCε activation and hepatic insulin resistance.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Introduction
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In this setting, PKCε, but not other isoforms of PKC, is activated.”
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · plain
“we observed that the development of diet-induced hepatic steatosis was associated with the activation of PKCε (7,10,12).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · plain
None of the sources cited for this claim have been checked yet.
In the paper
“This is important since DAG is a known activator of classic and novel isoforms of PKC and DAG concentrations have closely paralleled insulin resistance in other models (7,12).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“This is important since DAG is a known activator of classic and novel isoforms of PKC and DAG concentrations have closely paralleled insulin resistance in other models (7,12).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, in this model system, we specifically inhibit PKCε without altering other PKC isoforms or the concentration of PKC activators.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
ASOs are avidly taken up by the liver, where they inhibit specific genes of interest.
“ASOs are avidly taken up by the liver, where they inhibit specific genes of interest.”
The paper relies on this without support.
The control ASO does not have perfect complementarity to any known gene in public databases.
“The control ASO, ISIS-141923, has the sequence 5′-CCTTCCCT-GAAGGTTCCTCC-3′ and does not have perfect complementarity to any known gene in public databases.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is now strong evidence that nonalcoholic fatty liver disease has an important role in causing hepatic insulin resistance.1–3,23–27”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [24]
In the citing paper
“Recent studies have shown that increased hepatocellular concentrations of diacylglycerol in nonalcoholic fatty liver disease lead to activation of the protein kinase C epsilon isoform, resulting in reduced insulin signaling and hepatic insulin resistance.23–27”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Glucose tracer enrichment is identified as both M+6 and M+2
MinorThe methods describe the measured glucose enrichment as M+6, but then identify it as M+2 when specifying the mass ratio used. Both statements refer to the enrichment measurement for the same tracer.
“The atom percentage enrichment of glucoseM+6 was then measured by gas chromatographic/mass spectrometric analysis using a Hewlett-Packard 5890 gas chromatograph interfaced to a Hewlett-Packard 5971A mass-selective detector operating in the electron ionization mode (29).”
“GlucoseM+2 enrichment was determined from the m/z ratio 202:200.”
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
Kadowaki, T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29126 · Cited by 2,824
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
Self-citationGlobal Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030
Wild, S. H., Roglić, G., Green, A., Sicree, R. A., & King, H. O. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2569-a · Cited by 1,477
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Self-citationPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–400 of 497
McAuley, P. A., Hsu, F., Loman, K. K., Carr, J. J., Budoff, M. J., Szklo, M., Sharrett, A. R., & Ding, J. (2011) · Obesity · doi:10.1038/oby.2011.191 · Cited by 29
Do flavanols-rich natural products relieve obesity-related insulin resistance?
Engin, A. B., Tsatsakis, A. M., Tsoukalas, D., & Engin, A. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.12.055 · Cited by 30
“Fat-induced hepatic insulin resistance arises from excess lipid metabolites such as diacylglycerol-induced activation of PKC epsilon, which binds directly to and inhibits insulin receptor tyrosine kinase activity (Samuel et al., 2007).”
BackgroundDeconstructing the Role of PKC Epsilon in Glucose Homeostasis
Schmitz‐Peiffer, C. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.01.016 · Cited by 30
Fatty liver and insulin resistance in obese Zucker rats: No role for mitochondrial dysfunction
Flamment, M., Arvier, M., Gallois, Y., Simard, G., Malthièry, Y., Ritz, P., & Ducluzeau, P. (2008) · Biochimie · doi:10.1016/j.biochi.2008.05.003 · Cited by 29
Weismann, D., Erion, D. M., Ignatova-Todorava, I., Nagai, Y., Stark, R., Hsiao, J. J., Flannery, C. A., Birkenfeld, A. L., May, T., Kahn, M., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1984-5 · Cited by 30
“In the pathogenesis of insulin resistance, accumulation of diacylglycerol in muscle and liver leads to activation of novel protein kinase Cs (θ and ε, respectively) that inhibit insulin signalling and impair activation of AKT2 [1, 4, 5].”
BackgroundSelf-citationApolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease
Richart, C., Auguet, T., & Terra, X. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1005265 · Cited by 29
A polyphenol rescues lipid induced insulin resistance in skeletal muscle cells and adipocytes
Gogoi, B., Chatterjee, P., Mukherjee, S., Buragohain, A. K., Bhattacharya, S., & Dasgupta, S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.079 · Cited by 28
“In this tissue lipid oversupply induced activation of PKCe is primarily responsible for the loss of insulin sensitivity [4,9,13–16].”
BackgroundThe role of GPLD1 in chronic diseases
Cao, J., Zhou, A., Zhou, Z., Liu, H., & Jia, S. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31041 · Cited by 29
“It binds to insulin receptor and inhibits its tyrosine kinase activity, eventually triggering hepatic insulin resistance (Kumashiro et al., 2011; Samuel et al., 2007).”
BackgroundPKCδ silencing alleviates saturated fatty acid induced ER stress by enhancing SERCA activity
Lai, S., Li, Y., Kuang, Y., Cui, H., Yang, Y., Sun, W., Liu, K., Chen, D., Yan, Q., & Wen, L. (2017) · Bioscience Reports · doi:10.1042/bsr20170869 · Cited by 28
Masuda, S., Fujishima, Y., Maeda, N., Tsugawa-Shimizu, Y., Nakamura, Y., Tanaka, Y., Obata, Y., Fukuda, S., Nagao, H., Kita, S., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00319.2018 · Cited by 28
Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans
Rodrı́guez-Lee, M., Bondjers, G., & Camejo, G. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ef534f · Cited by 27
Gassaway, B. M., CARDONE, R. L., Padyana, A. K., Petersen, M. C., Judd, E. T., Hayes, S., Tong, S., Barber, K. W., Apostolidi, M., Abulizi, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.009 · Cited by 27
“Furthermore, knockdown of hepatic PKCε in rats protects against high-fat-diet (HFD)-induced insulin resistance (Gassaway et al., 2018; Petersen et al., 2016; Samuel et al., 2007).”
BackgroundMethodSelf-citationIRE1 impairs insulin signaling transduction of fructose-fed mice via JNK independent of excess lipid
Sun, R., Wang, H., Zeng, X., Chan, S. M. H., Li, S., Jo, E., Leung, S.-L., Molero, J. C., & Ye, J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.017 · Cited by 27
Chan, S. M. H., Zeng, X., Sun, R., Jo, E., Zhou, X., Wang, H., Li, S., Xu, A., Watt, M. J., & Ye, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.04.005 · Cited by 26
Insulin resistance due to lipid-induced signaling defects could be prevented by mahanine
Biswas, A., Bhattacharya, S., Dasgupta, S., Kundu, R., Roy, S. S., Pal, B. C., & Bhattacharya, S. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0257-4 · Cited by 25
“PKCe has been found to play a supportive role in fat induced hepatic insulin resistance by associating with IR, knocking down of PKCe expression could prevent rats from this pathogenesis [48].”
BackgroundKim, K., Bae, G. D., Lee, M., Park, E., Baek, D. J., Kim, C. Y., Jun, H., & Oh, Y. S. (2019) · Nutrients · doi:10.3390/nu11071522 · Cited by 26
Popov, V., Jornayvaz, F. R., Akgül, E. Ö., Kanda, S., Jurczak, M. J., Zhang, D., Abulizi, A., Majumdar, S. K., Guigni, B. A., Petersen, K. F., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-271999 · Cited by 24
Self-citationSong, J., Gao, J., Du, ., & Mao, X. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.03.044 · Cited by 24
Lee, G.-Y., Lim, J. H., Joung, H., & Yoon, D. (2024) · Nutrients · doi:10.3390/nu16203524 · Cited by 36
“Mechanistically, fat overload in the liver may lead to the accumulation of diacylglycerol, which activates protein kinase C ε (PKC ε ), impairing insulin signaling and leading to insulin resistance [22,47,48].”
BackgroundStearic Acid Serves as a Potent Inhibitor of Protein Tyrosine Phosphatase 1B
Tsuchiya, A., Kanno, T., & Nishizaki, T. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000356582 · Cited by 23
Smith, C. O., Wang, Y. T., Nadtochiy, S. M., Miller, J. H., Jonas, E. A., Dirksen, R. T., Nehrke, K. W., & Brookes, P. S. (2018) · The FASEB Journal · doi:10.1096/fj.201800139r · Cited by 23
Goedeke, L., Murt, K. N., Di Francesco, A., Camporez, J. P., Nasiri, A. R., Wang, Y., Zhang, X., Cline, G. W., de Cabo, R., & Shulman, G. I. (2022) · Aging Cell · doi:10.1111/acel.13539 · Cited by 22
Self-citationZeng, C., Han, Y., Huang, H., Yu, C., Ren, H., Shi, W., He, D., Huang, L., Yang, C., Wang, X., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283293c7b · Cited by 23
Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease
Yin, H., Shi, A., & Wu, J. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s367483 · Cited by 22
Advancements in MAFLD Modeling with Human Cell and Organoid Models
Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22
Dietary Phospholipids Ameliorate Fructose-Induced Hepatic Lipid and Metabolic Abnormalities in Rats
Mori, T., Kondo, H., Hase, T., & Murase, T. (2011) · Journal of Nutrition · doi:10.3945/jn.111.143602 · Cited by 22
Liao, B. M., Raddatz, K., Zhong, L., Parker, B. L., Raftery, M. J., & Schmitz‐Peiffer, C. (2014) · PROTEOMICS · doi:10.1002/pmic.201400202 · Cited by 22
Badi, R. M., Mostafa, D. G., Khaleel, E. F., & Satti, H. H. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13074 · Cited by 22
Greene, M. W., Burrington, C. M., Luo, Y., Ruhoff, M. S., Lynch, D. T., & Chaithongdi, N. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.10.008 · Cited by 21
“Glucose tolerance has also been shown to be normalized in the high saturated or unsaturated fat-fed PKCε-null mice [10,11].”
BackgroundSerup, A. K., Alsted, T. J., Jordy, A. B., Schjerling, P., Holm, C., & Kiens, B. (2016) · Diabetes · doi:10.2337/db16-0655 · Cited by 22
The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD
Östlund, C., Hernández‐Ono, A., & Shin, J. (2020) · Biology · doi:10.3390/biology9100338 · Cited by 21
Stout, M. B., Liu, L., & Belury, M. A. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201000413 · Cited by 21
Aguerd, O., Elhrech, H., Fessikh, M. E., Goh, K. W., Omari, N. E., Aanniz, T., & Bouyahya, A. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106705 · Cited by 24
Myronovych, A., Bhattacharjee, J., Salazar-Gonzalez, R.-M., Tan, B. K., Mowery, S., Ferguson, D. L., Ryan, K. K., Zhang, W., Zhao, X., Oehrle, M., et al. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00175.2020 · Cited by 20
Treatment of non-alcoholic fatty liver disease with focus on emerging drugs
Marchesini, G., Moscatiello, S., Agostini, F., Villanova, N., & Festi, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.531700 · Cited by 20
Mohan, S., Nair, A., Poornima, M. S., & Raghu, K. G. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110365 · Cited by 19
PKCδ regulates hepatic triglyceride accumulation and insulin signaling in Leprdb/db mice
Zhang, J., Burrington, C. M., Davenport, S. K., Johnson, A. K., Horsman, M. J., Chowdhry, S., & Greene, M. W. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.048 · Cited by 19
Brumer, R. P., Corrêa-Velloso, J. C., Thomas, S. J., Sandiford, O. A., Thomas, A. P., & Bartlett, P. J. (2023) · The Journal of Physiology · doi:10.1113/jp283691 · Cited by 18
Vatner, D. F., Snikeris, J., Popov, V., Perry, R. J., Rahimi, Y., & Samuel, V. T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140837 · Cited by 18
Self-citationKajimoto, K., Suemitsu, E., Sato, Y., Sakurai, Y., & Harashima, H. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00353 · Cited by 17
The role of TRIM family in metabolic associated fatty liver disease
Zhang, J., Zhang, Y., Ren, Z., Yan, D., & Li, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1210330 · Cited by 17
Pathogenesis of Nonalcoholic Fatty Liver Disease
Machado, M. V., & Diehl, A. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00025-2 · Cited by 17
Blood glucose regulation in context of infection
Wensveen, F. M., Šestan, M., Wensveen, T. T., & Polić, B. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2021.06.009 · Cited by 20
Physiological and pathophysiological actions of insulin in the liver
Kubota, N., Kubota, T., & Kadowaki, T. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0192 · Cited by 19
“Increased DAG activates PKC, which phosphorylates the serine residues in the β-subunit of the insulin receptor, resulting in impairment of the insulin receptor interaction with sig‐ naling proteins downstream, including IRS-1 and IRS-2 [83, 93, 94].”
Rabbani, N., & Thornalley, P. J. (2025) · Clinical Science · doi:10.1042/cs20257727 · Cited by 16
“Treatment of HFD-fed rats with antisense oligonucleotide against PKC ε protected against hepatic insulin resistance [110].”
Pan, J., Yin, J., Gan, L., & Xue, J. (2022) · Obesity Reviews · doi:10.1111/obr.13521 · Cited by 21
Intrahepatic lipid content is linked to insulin resistance in obese subjects
Sada, Y., Katabami, T., Asai, S., Sato, T., Furukawa, K., Ishii, S., Kato, H., KOBAYASHI, H., Kondo, A., Ohta, A., et al. (2011) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2010.12.007 · Cited by 16
Zhang, Z., Shu, G., Zhu, X., Guo, J., Cai, H., Wang, S., Wang, L., Gao, P., Xi, Q., Zhang, Y., et al. (2014) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/2049-1891-5-29 · Cited by 16
“Considering that DGAT catalyzes TAG synthesis through DAG, numerous reports have shown that lower DGAT2 expression resulted in lower DAG content [30,31], subsequently activating protein kinase Cε (PKCε) [32-35].”
BackgroundKim, D., & Choi, H. (2019) · Liver Research · doi:10.1016/j.livres.2019.03.001 · Cited by 16
Xia, M., Chen, L., Wu, L., Ma, H., Li, Q., Aleteng, Q., Hu, Y., He, W., Gao, J., Lin, H., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15372 · Cited by 16
Mungamuri, S. K., Sinha, S. N., & Javvadi, Y. (2020) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2020035839 · Cited by 17
Impaired PI3 K Akt expression in liver and skeletal muscle of ovariectomized rats
Wang, Y., Li, B., Zhang, W., Liu, Y., Xue, P., Ma, J., & Li, Y. (2013) · Endocrine · doi:10.1007/s12020-013-9894-1 · Cited by 16
Identification of Protein Kinase C Isoforms Involved in Type 1 Diabetic Encephalopathy in Mice
Zheng, J., Wang, Y., Han, S., Luo, Y., Sun, X., Zhu, N. W., Zhao, L., & Li, J. (2018) · Journal of Diabetes Research · doi:10.1155/2018/8431249 · Cited by 16
“The key role of nPKCε for fat-induced hepatic insulin resistance is demonstrated with antisense oligonucleotide-mediated knockdown of nPKCε in high-fat feeding rats [18].”
BackgroundWang, J., Xu, S., Gao, J., Zhang, L., Zhang, Z., Yang, W., Li, Y., Liao, S., Zhou, H., Liu, P., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00016.2018 · Cited by 16
Kumari, D., Gautam, J., Sharma, V., Gupta, S. K., Sarkar, S., Jana, P., Singhal, V., Babele, P., Kamboj, P., Bajpai, S., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22051 · Cited by 15
Factors Affecting Insulin-Regulated Hepatic Gene Expression
Guan, H.-P., & Chen, G. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00006-5 · Cited by 15
Lutkewitte, A. J., Singer, J., Shew, T. M., Martino, M. R., Hall, A. M., He, M., & Finck, B. N. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101204 · Cited by 15
“recently reported that that liver-specific KO of protein kinase C ε (PKCε) did not phenocopy previous ASO work conducted in rats and found instead that deletion of PKCε in adipose tissue, which is often targeted by ASOs as well, produced an insulinsensitive phenotype [33,34].”
BackgroundThe Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity
Cusi, K. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-260-1_1 · Cited by 15
Kim, J., Kim, Y. S., Lee, H. A., Lim, J. Y., Kim, M. K., Kwon, O., Ko, H.-C., Kim, S.-J., Shin, J.-H., & Kim, Y. (2014) · Journal of Medicinal Food · doi:10.1089/jmf.2013.2916 · Cited by 15
Bandô, Y., & Geisler, J. G. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104561 · Cited by 14
Self-citationInterplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
Ramadan, M. S., Russo, V., Nigro, G., Durante‐Mangoni, E., & Zampino, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081569 · Cited by 15
Pathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 14
Duration of rise in free fatty acids determines salicylate's effect on hepatic insulin sensitivity
Pereira, S., Yu, W., Frigolet, M. E., Beaudry, J. L., Shpilberg, Y., Park, E., Dirlea, C., Nyomba, B. L. G., Riddell, M. C., Fantus, I. G., et al. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0214 · Cited by 13
“(Samuel et al. 2007).”
BackgroundBioactive lipids and metabolic syndrome—a symposium report
DeVito, L. M., Dennis, E. A., Kahn, B. B., Shulman, G. I., Witztum, J. L., Sadhu, S., Nickels, J. T., Spite, M. R., Smyth, S. S., & Spiegel, S. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14752 · Cited by 12
Self-citationShi, Y., Lam, S. M., Liu, H., Luo, G., Zhang, J., Yao, S., Li, J., Zheng, L., Xu, N., Zhang, X., et al. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.08.003 · Cited by 13
Self-citationCapuani, B., Pacifici, F., Pastore, D., Palmirotta, R., Donadel, G., Arriga, R., Bellia, A., Daniele, N. D., Rogliani, P., Abete, P., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.029 · Cited by 13
Flavin-Containing Monooxygenase 3 Reduces Endoplasmic Reticulum Stress in Lipid-Treated Hepatocytes
Liao, B. M., McManus, S. A., Hughes, W. E., & Schmitz‐Peiffer, C. (2016) · Molecular Endocrinology · doi:10.1210/me.2015-1217 · Cited by 14
Preventing obesity, insulin resistance and type 2 diabetes by targeting MT1-MMP
Asthana, P., & Wong, H. L. X. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167081 · Cited by 13
Mahmoudi, A. A., Rostami, M., Hajihasani, M. M., Sukhorukov, V. N., Kesharwani, P., & Sahebkar, A. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.112866 · Cited by 12
Zhang, Y., Zhao, H., Zhao, J., Lv, W., Jia, X., Lu, X., Zhao, X., & Xu, G. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00760 · Cited by 13
Role of Lipid Droplet Proteins in the Development of NAFLD and Hepatic Insulin Resistance
Minehira, K., & Gual, P. (2018) · InTech eBooks · doi:10.5772/intechopen.71572 · Cited by 12
Selby, L. V., Ejaz, A. M., Brethauer, S. A., & Pawlik, T. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1721457 · Cited by 12
Inafuku, M., Matsuzaki, G., & Oku, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128676 · Cited by 11
Khamaisie, H., Sussan, S., Tal, M., Najajreh, Y., Ruthardt, M., & Mahajna, J. A. (2011) · PubMed · Cited by 11
Lee, D., Shin, Y., Roh, J., Ahn, J., Jeong, S., Shin, S. C., & Yoon, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124256 · Cited by 11
RetractedPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 11
High-fat-diet-induced hepatic insulin resistance per se attenuates murine de novo lipogenesis
Goedeke, L., Strober, J. W., Suh, R., Paolella, L. M., Li, X., Rogers, J. C., Petersen, M. C., Nasiri, A. R., Casals, G., Kahn, M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111175 · Cited by 10
Self-citationSamuel, V. T., Petersen, M. C., Gassaway, B. M., Vatner, D. F., Rinehart, J., & Shulman, G. I. (2019) · Hepatology · doi:10.1002/hep.30829 · Cited by 10
Self-citationThe beneficial impact of curcumin on cardiac lipotoxicity
Abolfazli, S., Butler, A. E., Kesharwani, P., & Sahebkar, A. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae102 · Cited by 10
Targeting Hepatic Glycerolipid Synthesis and Turnover to Treat Fatty Liver Disease
Schweitzer, G. G., & Finck, B. N. (2014) · Advances in Hepatology · doi:10.1155/2014/498369 · Cited by 10
Chen, L., Yu, S., Hong, S., Lin, X., Zhu, X., Cao, X., Li, Y., & Xiao, H. (2022) · Drug Development Research · doi:10.1002/ddr.22020 · Cited by 9
“In our study, genes (e.g., PEPCK and G6Pase) involved in the insulin signaling pathway and regulated hepatic gluconeogenesis (Samuel et al., 2007; Titchenell et al., 2016) were downregulated in the ATM‐treated group.”
BackgroundMechanisms underlying fat-induced hepatic insulin resistaNce
Park, E., & Giacca, A. (2007) · Future Lipidology · doi:10.2217/17460875.2.5.503 · Cited by 9
It's what you do with the fat that matters!
Bruce, C. R., & Febbraio, M. A. (2007) · Nature Medicine · doi:10.1038/nm1007-1137 · Cited by 9
Beddow, S. A., Gattu, A. K., Vatner, D. F., Paolella, L. M., Alqarzaee, A. A., Tashkandi, N., Popov, V., CHURCH, C. D., Rodeheffer, M. S., Cline, G. W., et al. (2018) · Endocrinology · doi:10.1210/en.2018-00630 · Cited by 9
Self-citationPathogenesis of NAFLD and NASH
Maher, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_4 · Cited by 8
Roura-Guiberna, A., Hernández-Aranda, J., Ramírez‐Flores, C. J., Mondragón‐Flores, R., Garibay-Nieto, N., Queipo-García, G. E., Laresgoiti‐Servitje, E., Soh, J., & Olivares-Reyes, J. A. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.10.013 · Cited by 8
Aerobic Exercise Prevents High-Fat-Diet-Induced Adipose Tissue Dysfunction in Male Mice
Guo, Q., Li, N., Shi, H., Gan, Y., Wang, W., Jia, J., & Zhou, Y. (2024) · Nutrients · doi:10.3390/nu16203451 · Cited by 7
“However, recent reports suggest that the activation of IR may precede chronic inflammation or even occur independently [42–45].”
BackgroundEmerging Roles of Post-Translational Modifications in Metabolic Homeostasis and Type 2 Diabetes
Kim, Y. K., & Kim, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311552 · Cited by 8
“Lipid-activated PKC θ in skeletal muscle and PKC ε in liver impair insulin receptor signaling and contribute to insulin resistance in nutrient excess [66,67].”
Osei‐Ntansah, A., OLIVER, T. R., Lofton, T., Falzarano, C., Carr, K., Huang, R., Wilson, A., Damaser, E., Harvey, G., Rahman, M. A., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae021 · Cited by 7
TRIB2-Mediated Modulation of AMPK Promotes Hepatic Insulin Resistance
Wang, D., Kang, X., Zhang, L., Guo, Y., Zhang, Z., Ren, H., & Yuan, G. (2024) · Diabetes · doi:10.2337/db23-0195 · Cited by 7
Role of ectopic fat in the pathogenesis of insulin resistance
Kantartzis, K., Totsikas, C., Häring, H., & Stefan, N. (2009) · Clinical Lipidology · doi:10.2217/clp.09.35 · Cited by 7
Pedersen, D. J., Diakanastasis, B., Stöckli, J., & Schmitz‐Peiffer, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058046 · Cited by 7
“In the liver, PKCe may also more directly inhibit insulin receptor activation itself [3].”
BackgroundMitochondria in Liver Diseases
Grattagliano, I., de Bari, O., Palo, D. D., Montecucco, F., Carbone, F., Oliveira, P. J., Wang, D. Q. ‐., & Portincasa, P. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_7 · Cited by 7
Sato, T., Katabami, T., Furukawa, K., Narimatsu, H., Hashimoto, T., Nakajima, Y., Ohta, A., Sasaoka, T., & Tanaka, Y. (2011) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2011.09.001 · Cited by 7
Ruderman, N. B., & Shulman, G. I. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00044-7 · Cited by 7
Self-citationNon‐Alcoholic Fatty Liver Disease: A Pathophysiological Perspective
Fuchs, M. A., & Sanyal, A. J. (2009) · Wiley eBooks · doi:10.1002/9780470747919.ch45 · Cited by 7
Non‐alcoholic Fatty Liver Disease and Insulin Resistance
Petersen, M. C., Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch37 · Cited by 10
Self-citationPlasma Lipid Metabolites, Clinical Glycemic Predictors, and Incident Type 2 Diabetes
Begzati, A., Godinez‐Macias, K. P., Long, T., Watrous, J. D., Moranchel, R., Kantz, E. D., Tuomilehto, J. O., Havulinna, A. S., Niiranen, T., Jousilahti, P., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2266 · Cited by 6
Al-Busaidi, A., Alabri, O., Alomairi, J., Elsharaawy, A., Lawati, A. A., Lawati, H. A., & Das, S. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998281910231231051814 · Cited by 7
Ghoshal, K., Luther, J. M., Pakala, S., Chetyrkin, S. V., Falck, J. R., Zent, R., Wasserman, D. H., & Pozzi, A. (2024) · Diabetes · doi:10.2337/db23-0493 · Cited by 6
Metadata
- Authors
- Samuel, V. T., Liu, Z.-X., Wang, A., Beddow, S. A., Geisler, J. G., Kahn, M., Zhang, X.-M., Monia, B. P., Bhanot, S., & Shulman, G. I.
- Affiliations
- Yale University (US)
- Ionis Pharmaceuticals (United States) (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Shulman, Gerald I.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-03-01
- Volume
- 117
- Issue
- 3
- Pages
- 739-745
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1797607
- OpenAlex
- W2094051977
- Semantic Scholar
- 26809f321fcb7f6db237dd2f0abf76fa612e6a2f
- Cited by
- 497
- References
- 39
- Citations by year
- 2026: 17 · 2025: 10 · 2024: 24 · 2023: 14 · 2022: 19 · 2021: 12 · 2020: 25 · 2019: 26 · 2018: 36 · 2017: 21 · 2016: 37 · 2015: 29 · 2014: 28 · 2013: 25 · 2012: 27
- FWCI
- 24.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (P30 DK45735, R01 DK-40936, DK40936)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, U24DK059635, P30DK045735)
- National Center for Research Resources (K23RR017404, K23 RR-17404)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- protein kinase C epsilon, hepatic insulin resistance, non-alcoholic fatty liver disease, hepatic steatosis, high-fat feeding, insulin receptor, antisense oligonucleotide knockdown, type 2 diabetes, insulin signaling, therapeutic target
- MeSH terms
- Animals, Fatty Liver, Insulin, Insulin Resistance, Male, Receptor, Insulin, Signal Transduction, Oligonucleotides, Antisense, Rats, Sprague-Dawley, Lipid Metabolism, Rats, Protein Kinase C-epsilon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
